Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Open accessThe DOI matches its Crossref record; 131 of the 136 references it cites were found in a registry or an index.
Abstract
Irinotecan has been used in the treatment of various malignancies for many years. Still, the knowledge regarding this drug is expanding. The pharmacogenetics of the drug is the crucial component of response to irinotecan. Furthermore, new formulations of the drug are introduced in order to better deliver the drug and avoid potentially life-threatening side effects. Here, we give a comprehensive overview on irinotecan’s molecular mode of action, metabolism, pharmacogenetics, and toxicity. Moreover, this article features clinically used combinations of the drug with other anticancer agents and introduces novel formulations of drugs (e.g., liposomal formulations, dendrimers, and nanoparticles). It also outlines crucial mechanisms of tumor cells’ resistance to the active metabolite, ethyl-10-hydroxy-camptothecin (SN-38). We are sure that the article will constitute an important source of information for both new researchers in the field of irinotecan chemotherapy and professionals or clinicians who are interested in the topic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Mechanisms of action for human topoisomerases. (A) Topoisomerase IA binds to DNA at a particular binding site, and then claves one strand, forming a transient 5′-phosphotyrosyl bond. The other DNA strand is transferred through the resultant break, allowing DNA to relax. Religation ends the process. (B) Toposiomerase IB works in a controlled rotation mechanism and in contrast to type IA enzymes forms a 3′-phosphotyrosyl bond with a DNA molecule. Both type I (A&B) topoisomerases do not require ATP hydrolysis as a source of energy. (C) Topoisomerase II binds to both ends of the DNA molecule, forms a double-strand break, and passes a segment of dsDNA through. This reaction is ATP-dependent [19].](https://figures.cochat.ai/paper-figures/7f178116e98944b58d61966403e83683/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-1.jpg)


![Figure 4 Mechanisms of cell death induced by irinotecan. The ternary irinotecan–topoisomerase I–nicked DNA complex with topoisomerase I (Topo I) inhibitor (SN-38) disables religation of the nicked strand and prevents topoisomerase release. Collision of the formed complex with advancing replication forks results in the formation of double-strand breaks (DSBs). This is followed by DNA damage response (DDR) signaling and TP53-induced gene expression of pro-apoptotic genes such as apoptosis regulator (BAX), phorbol-12-myristate-13-acetate-induced protein 1 (NOXA), or p53 up-regulated modulator of apoptosis (PUMA). Furthermore, down-regulation of the Bcl-2-like protein 1 isoform protein (BCL-xL) protein allows BAX and Bcl-2 homologous antagonist (BAK) embedding into the mitochondrial membrane and the formation of pores that allow the release of cytochrome C (cytC) from mitochondria and the subsequent formation of apoptosome with apoptotic protease-activating factor 1 (APAF-1) protein and procaspase-9. The activation of procaspase to caspase 9 (Casp-9) results in proteolytic cleavage and the conversion of procaspase 3 into active caspase 3 (Casp-3), which executes apoptosis [37,38,44,49,51].](https://figures.cochat.ai/paper-figures/e0271a41931a4560ab503b6a9b0123a1/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-4.jpg)
![Figure 5 Overview of irinotecan metabolism. CPT-11 is a prodrug that is converted to active metabolite ethyl-10-hydroxy-camptothecin (SN-38) by liver carboxylesterase converting enzymes (CES1/2) and is then transported to the liver by 1B1 polypeptide (OATP1B1) and inactivated by microsomal uridine 5′-diphospho-glucuronosyltransferase enzymes (UGTs): UGT1A1 and UGT1A9. Irinotecan is transported to bile by a group of the ATP-binding cassette transporters (ABC transporters): ABCB1, ABCC1, ABCC2, and ABCG2. Irinotecan is efficiently metabolized by cytochrome P450 enzymes: CYP3A4 and CYP3A5. This results in the generation of less active metabolites APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin) and NPC (7-ethyl-10-[4-amino-1-piperidino] carbonyloxycamptothecin). NPC (but not APC) can be further converted to SN-38 by CES1, and CES2 gut microbiota may also participate in irinotecan metabolism by the production of β-glucuronidase, which catalyzes the breakdown of SN-38G to SN-38. The inhibition of topoisomerase I (TOP1) results in DNA damage, replication fork arrest, and apoptotic cell death [53,54,55,56,57,58,59,60,61,62].](https://figures.cochat.ai/paper-figures/5036a4be7c55479baa6b8b63ea3ebd23/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Irinotecan (IRI) is a chemotherapeutic agent that inhibits topoisomerase I activity, which in turn inhibits both DNA replication and transcription49.”
From A statistical framework for high-content phenotypic profiling using cellular feature distributions (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredIn the citing paper
“Irinotecan exerts a cytotoxic effect by inhibiting DNA replication and transcription by targeting topoisomerase 1 (TOP-1) [87].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
DNA Topoisomerases: Structure, Function, and Mechanism
Champoux, J. J. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.369 · Cited by 2,743
Cellular roles of DNA topoisomerases: a molecular perspective
Wang, J. C. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm831 · Cited by 2,353
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
Self-citationVauthey, J.-N., Pawlik, T. M., Ribero, D., Wu, T.-T., Zorzi, D., Hoff, P. M., Xiong, H. Q., Eng, C., Lauwers, G. Y., Mino-Kenudson, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3074 · Cited by 1,300
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
Pommier, Y., Sun, Y., Huang, S.-Y. N., & Nitiss, J. L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.111 · Cited by 950
DNA topoisomerase II and its growing repertoire of biological functions
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2608 · Cited by 885
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
Koopman, M., Antonini, N. F., Douma, J., Wals, J., Honkoop, A. H., Erdkamp, F. L., de Jong, R. S., Rodenburg, C. J., Vreugdenhil, G., Loosveld, O. J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61086-1 · Cited by 630
Drug resistance and new therapies in colorectal cancer
Jeught, K. V. D., Xu, H.-C., Li, Y.-J., Lu, X.-B., & Ji, G. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i34.3834 · Cited by 597
Analysis of anticancer drugs: A review
Nussbaumer, S., Bonnabry, P., Veuthey, J.-L., & Fleury-Souverain, S. (2011) · Talanta · doi:10.1016/j.talanta.2011.08.034 · Cited by 568
Lara, P. N., Natale, R., Crowley, J., Lenz, H. J., Redman, M. W., Carleton, J. E., Jett, J., Langer, C. J., Kuebler, J. P., Dakhil, S. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1061 · Cited by 525
Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism
Froelich-Ammon, S. J., & Osheroff, N. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.21429 · Cited by 505
Camptothecin: current perspectives
Thomas, C. J., Rahier, N. J., & Hecht, S. M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.11.036 · Cited by 451
Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Stein, A., Voigt, W., & Jordan, K. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009355164 · Cited by 431
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Ahmed, S., Zhou, Z., Zhou, J., & Chen, S.-Q. (2016) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.03.008 · Cited by 371
Wang-Gillam, A., Hubner, R. A., Siveke, J. T., Von Hoff, D. D., Belanger, B., de Jong, F. A., Mirakhur, B., & Chen, L.-T. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.007 · Cited by 342
Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB
Koster, D. A., Croquette, V., Dekker, C., Shuman, S., & Dekker, N. H. (2005) · Nature · doi:10.1038/nature03395 · Cited by 324
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Fujita, K.-I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12234 · Cited by 323
Nozawa, T., Minami, H., Sugiura, S., Tsuji, A., & Tamai, I. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001909 · Cited by 316
The long story of camptothecin: From traditional medicine to drugs
Martino, E., Della Volpe, S., Terribile, E., Benetti, E., Sakaj, M., Centamore, A., Sala, A., & Collina, S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.085 · Cited by 296
DNA transport by a type II DNA topoisomerase: Evidence in favor of a two-gate mechanism
Roca, J., & Wang, J. C. (1994) · Cell · doi:10.1016/0092-8674(94)90222-4 · Cited by 288
Braun, M. S., Richman, S. D., Quirke, P., Daly, C., Adlard, J. W., Elliott, F., Barrett, J. H., Selby, P., Meade, A. M., Stephens, R. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5580 · Cited by 280
Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Innocenti, F., Kroetz, D. L., Schuetz, E., Dolan, M. E., Ramírez, J., Relling, M., Chen, P., Das, S., Rosner, G. L., & Ratain, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6300 · Cited by 262
Bush, N. G., Evans-Roberts, K., & Maxwell, A. (2015) · EcoSal Plus · doi:10.1128/ecosalplus.esp-0010-2014 · Cited by 238
Irinotecan in the treatment of colorectal cancer
Fuchs, C., Mitchell, E. P., & Hoff, P. M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.07.001 · Cited by 237
Wang, H., Agarwal, P., Zhao, S., Xu, R. X., Yu, J., Lu, X., & He, X. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.08.048 · Cited by 218
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Santos, A., Zanetta, S., Cresteil, T., Deroussent, A., Pein, F. J. L., Raymond, É., Vernillet, L., Risse, M., Boige, V., Gouyette, A., et al. (2000) · PubMed · Cited by 213
Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors
Pommier, Y., Pharm, D., Fesen, M. R., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., & Kohn, K. W. (1994) · Cancer Investigation · doi:10.3109/07357909409021413 · Cited by 207
Han, J., Lim, H., Yoo, Y., Shin, E. S., Park, Y. H., Lee, S. Y., Lee, J., Lee, D. H., Kim, H. T., & Lee, J. S. (2007) · Cancer · doi:10.1002/cncr.22760 · Cited by 195
Ishida, R., Miki, T., Narita, T., Yui, R., Sato, M., Utsumi, K. R., Tanabe, K., & Andoh, T. (1991) · PubMed · Cited by 192
Pharmacogenetics of irinotecan metabolism and transport: An update
Smith, N. F., Figg, W. D., & Sparreboom, A. (2006) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.06.045 · Cited by 190
Bisacchi, G. S., & Manchester, J. I. (2015) · ACS Infectious Diseases · doi:10.1021/id500013t · Cited by 180
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
Teicher, B. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.10.016 · Cited by 176
International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms
Giacomini, K. M., Balimane, P. V., Cho, S. K., Eadon, M., Edeki, T., Hillgren, K. M., Huang, S.-M., Sugiyama, Y., Weitz, D., Wen, Y., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.12 · Cited by 165
Capranico, G., Marinello, J., & Chillemi, G. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00966 · Cited by 150
Irinotecan (CPT-11): Recent Developments and Future Directions–Colorectal Cancer and Beyond
Rothenberg, M. L. (2001) · The Oncologist · doi:10.1634/theoncologist.6-1-66 · Cited by 144
Ciotti, M., Basu, N. K., Brangi, M., & Owens, I. S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0453 · Cited by 141
Carrato, A., Swieboda-Sadlej, A., Staszewska-Skurczynska, M., Lim, R., Roman, L., Shparyk, Y., Bondarenko, I., Jonker, D. J., Sun, Y., De la Cruz, J. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1930 · Cited by 136
DNA supercoiling is a fundamental regulatory principle in the control of bacterial gene expression
Dorman, C. J., & Dorman, M. J. (2016) · Biophysical Reviews · doi:10.1007/s12551-016-0238-2 · Cited by 133
Structural studies of type I topoisomerases
Baker, N. M., Rajan, R., & Mondragón, A. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn1009 · Cited by 129
Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets
Gilbert, D. C., Chalmers, A. J., & El-Khamisy, S. F. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.498 · Cited by 118
Kubota, K., Hida, T., Ishikura, S., Mizusawa, J., Nishio, M., Kawahara, M., Yokoyama, A., Imamura, F., Takeda, K., Negoro, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70511-4 · Cited by 117
DNA supercoiling is a fundamental regulatory principle in the control of bacterial gene expression
Dorman, C. J., & Dorman, M. J. (2016) · Biophysical Reviews · doi:10.1007/s12551-016-0205-y · Cited by 114
Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38
Paoluzzi, L., Singh, A. S., Price, D. K., Danesi, R., Mathijssen, R. H. J., Verweij, J., Figg, W. D., & Sparreboom, A. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004267159 · Cited by 113
Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma
Paillas, S., Boissière‐Michot, F., Bibeau, F., Denouël, A., Mollévi, C., Causse, A., Denis, V., Vié, N., Marzi, L., Cortijo, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2726 · Cited by 106
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
Innocenti, F., Iyer, L., & Ratain, M. J. (2001) · PubMed · Cited by 98
New Topoisomerase I mutations are associated with resistance to camptothecin
Gongora, C., Vié, N., Tuduri, S., Denis, V., Causse, A., Auzanneau, C., Collod‐Béroud, G., Coquelle, A., Pasero, P., Pourquier, P., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-64 · Cited by 94
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
Singh, A. S., Paoluzzi, L., Price, D. K., Danesi, R., Mathijssen, R. H. J., Verweij, J., Figg, W. D., & Sparreboom, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.2072 · Cited by 90
Targeted drug delivery systems for the intracellular delivery of macromolecular drugs
Koning, G. A., & Storm, G. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02699-0 · Cited by 85
Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients
Bao, X., Wu, J., Kim, S., LoRusso, P. M., & Li, J. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1275 · Cited by 76
Synergistic Cytotoxicity of Irinotecan and Cisplatin in Dual-Drug Targeted Polymeric Nanoparticles
Valencia, P. M., Pridgen, E. M., Perea, B., Gadde, S., Sweeney, C., Kantoff, P. W., Bander, N. H., Lippard, S. J., Langer, R., Karnik, R., et al. (2013) · Nanomedicine · doi:10.2217/nnm.12.134 · Cited by 75
Was, H., Czarnecka, J., Kominek, A., Barszcz, K., Bernas, T., Piwocka, K., & Kaminska, B. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1385675 · Cited by 75
Karki, N., Tiwari, H., Pal, M., Chaurasia, A., Bal, R., Joshi, P., & Sahoo, N. G. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.05.022 · Cited by 75
Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
Nielsen, D. L., Palshof, J. A., Brünner, N., Stenvang, J., & Viuff, B. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091926 · Cited by 69
SAWADA, S., MATSUOKA, S.-I., Nokata, K., Nagata, H., Furuta, T., YOKOKURA, T., & MIYASAKA, T. (1991) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.39.3183 · Cited by 68
Effect of p53 Status and STAT1 on Chemotherapy-Induced, Fas-Mediated Apoptosis in Colorectal Cancer
McDermott, U., Longley, D. B., Galligan, L., Allen, W., Wilson, T., & Johnston, P. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0961 · Cited by 66
Enzinger, P. C., Kulke, M. H., Clark, J. W., Ryan, D. P., Kim, H. T., Earle, C. C., Vincitore, M., Michelini, A. L., Mayer, R. J., & Fuchs, C. S. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-3038-2 · Cited by 66
Mohammad, A. S., Griffith, J. I. G., Adkins, C. E., Shah, N., Sechrest, E. R., Dolan, E. L., Terrell-Hall, T. B., Hendriks, B. S., Lee, H., & Lockman, P. R. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2278-0 · Cited by 64
Glucuronidation of SN‐38, the Active Metabolite of Irinotecan, by Human Hepatic Microsomes
Haaz, M., Rivory, L. P., Jantet, S., Ratanasavanh, D., & Robert, J. (1997) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1997.tb00289.x · Cited by 63
Takeba, Y., Kumai, T., Matsumoto, N., Nakaya, S., Tsuzuki, Y., Yanagida, Y., & Kobayashi, S. (2007) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0070442 · Cited by 62
Topoisomerase I Inhibitors: An Overview of the Camptothecin Analogs
Burris, H. A., & Jones, S. F. (1994) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30176-x · Cited by 59
Type IA topoisomerases can be “magicians” for both DNA and RNA in all domains of life
Ahmad, M., Xu, D., & Wang, W. (2017) · RNA Biology · doi:10.1080/15476286.2017.1330741 · Cited by 57
Onishi, H., Machida, Y., & Machida, Y. (2003) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.26.116 · Cited by 55
Gene Expression Profiling of the Irinotecan Pathway in Colorectal Cancer
Yu, J., Shannon, W. D., Watson, M. A., & McLeod, H. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1254 · Cited by 55
Tunable self-assembly of Irinotecan-fatty acid prodrugs with increased cytotoxicity to cancer cells
Zhang, C., Jin, S., Xue, X., Zhang, T., Jiang, Y., Wang, P. C., & Liang, X. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb00612d · Cited by 55
Shaojun, C., Li, H., Haixin, H., & Guisheng, L. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1414754 · Cited by 54
Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
Makiyama, A., Arimizu, K., Hirano, G., Makiyama, C., Matsushita, Y., Shirakawa, T., Ohmura, H., Komoda, M., Uchino, K., Inadomi, K., et al. (2017) · Gastric Cancer · doi:10.1007/s10120-017-0759-9 · Cited by 52
Stenvang, J., Kümler, I., Nygård, S. B., Smith, D. H., Nielsen, D., Brünner, N., & Moreira, J. M. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00313 · Cited by 51
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma
Wang, L., Liang, L., Yang, T., Qiao, Y., Xia, Y., Liu, L., Li, C., Lu, P., & Jiang, X. (2017) · Medicine · doi:10.1097/md.0000000000009053 · Cited by 51
Paulík, A., Nekvindová, J., & Filip, S. (2018) · Tumori Journal · doi:10.1177/0300891618811283 · Cited by 51
ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia
Li, M., Seiser, E. L., Baldwin, R. M., Ramirez, J., Ratain, M. J., Innocenti, F., & Kroetz, D. L. (2018) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.75 · Cited by 50
Han, J.-Y., Shin, E., Lee, Y.-S., Ghang, H.-Y., Kim, S.-Y., Hwang, J.-A., Kim, J., & Lee, J. S. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2012.24 · Cited by 47
Yang, Y., Zhou, M., Hu, M., Cui, Y., Zhong, Q., Liang, L., & Huang, F. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13028 · Cited by 47
Guemei, A. A. S., Cottrell, J., Band, R. A., Hehman, H., Prudhomme, M., Pavlov, M. V., Grem, J. L., Ismail, A. S., Bowen, D., Taylor, R. E., et al. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000258 · Cited by 46
LaBonte, M. J., Manegold, P. C., Wilson, P. M., Fazzone, W., Louie, S. G., Lenz, H., & Ladner, R. D. (2009) · International Journal of Cancer · doi:10.1002/ijc.24658 · Cited by 46
Wang, Y., Yang, L., Zhang, J., Zhou, M., Shen, L., Deng, W., Liang, L., Hu, R., Yang, W., Yao, Y., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4514 · Cited by 40
Alamgeer, M., Watkins, D. N., Banakh, I., Kumar, B., Gough, D. J., Markman, B., & Ganju, V. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0555-8 · Cited by 40
Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells
Reita, D., Bour, C., Benbrika, R., Groh, A., Pencreach, E., Guérin, É., & Guénot, D. (2019) · Cancers · doi:10.3390/cancers11101581 · Cited by 40
Alibolandi, M., Abnous, K., Anvari, S., Mohammadi, M., Ramezani, M., & Taghdisi, S. M. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1446969 · Cited by 39
Natoli, C., Perrucci, B., Perrotti, F., Falchi, L., & Iacobelli, S. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791517208 · Cited by 39
Sanoff, H. K., Goldberg, R. M., Ivanova, A., O'Reilly, S., Kasbari, S. S., Kim, R. D., McDermott, R., Moore, D. T., Zamboni, W., Grogan, W., et al. (2018) · Cancer · doi:10.1002/cncr.31552 · Cited by 38
Xu, L. L., Zhu, Y., Shao, J., Chen, M., Yan, H., Li, G., Zhu, Y., Xu, Z., Yang, B., Luo, P., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.55 · Cited by 37
Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study
Wu, C., Zhang, Y., Yang, D., Zhang, J., Ma, J., Cheng, D., Chen, J., & Deng, L. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s187906 · Cited by 37
Vétillard, A., Jonchère, B., Moreau, M., Toutain, B., Henry, C., Fontanel, S., Bernard, A.-C., Campone, M., Guette, C., & Coqueret, O. (2015) · Oncotarget · doi:10.18632/oncotarget.6126 · Cited by 36
Ge, S., Tu, Y., & Hu, M. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0076-8 · Cited by 35
Minderman, H., Conroy, J. M., O’Loughlin, K. L., McQuaid, D., Quinn, P. K., Li, S., Pendyala, L., Nowak, N. J., & Baer, M. R. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0048 · Cited by 34
Topoisomerases, chromatin and transcription termination
Durand‐Dubief, M., Svensson, J. P., Persson, J., & Ekwall, K. (2011) · Transcription · doi:10.4161/trns.2.2.14411 · Cited by 34
Shi, Y., Hu, Y., Hu, X., Li, X., Lin, L., & Han, X. (2015) · Thoracic Cancer · doi:10.1111/1759-7714.12303 · Cited by 34
Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats
Masuda (1994) · Oncology Reports · doi:10.3892/or_00000066 · Cited by 33
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
Musa, F., Pothuri, B., Blank, S. V., Ling, H. T., Speyer, J. L., Curtin, J. P., Boyd, L. R., Li, X., Goldberg, J. D., Muggia, F. M., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.11.043 · Cited by 32
Self-assembled polypeptide nanoparticles for intracellular irinotecan delivery
Zashikhina, N., Volokitina, M. V., Korzhikov-Vlakh, V. A., Tarasenko, I. I., Lavrentieva, A. V., Scheper, T. H., Rühl, E., Орлова, Р. В., Tennikova, T. B., & Korzhikova‐Vlakh, E. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.07.022 · Cited by 32
BR2 and CyLoP1 enhance in-vivo SN38 delivery using pegylated PAMAM dendrimers
Mahmoudi, A., Jaafari, M. R., Ramezanian, N., Gholami, L., & Malaekeh‐Nikouei, B. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.04.037 · Cited by 31
Irinotecan plus Oxaliplatin: a Promising Combination for Advanced Colorectal Cancer
Wasserman, E., Sutherland, W., & Cvitkovic, E. (2001) · Clinical Colorectal Cancer · doi:10.3816/ccc.2001.n.015 · Cited by 30
The role of p38 in irinotecan-induced DNA damage and apoptosis of colon cancer cells
Rudolf, E., Králová, V., Rudolf, K., & John, S. (2013) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2013.02.002 · Cited by 30
Combined inhibition of topoisomerases I and II - is this a worthwhile/feasible strategy?
Vasey, P. A., & Kaye, S. B. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.568 · Cited by 29
Haug, K., Kravik, K., & Angelis, P. M. D. (2008) · PubMed · Cited by 28
Stathopoulos, G. P., Dimitroulis, J., Antoniou, D., Katis, C., Tsavdaridis, D., Armenaki, O., Marosis, C., Michalopoulou, P., Grigoratou, T., & Stathopoulos, J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602827 · Cited by 27
Woo, W., Carey, E. T., & Choi, M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s167590 · Cited by 27
Bennouna, J., Deslandres, M., Senellart, H., de Labareyre, C., Ruiz-Soto, R., Wixon, C., Botbyl, J., Suttle, A. B., & Delord, J.-P. (2015) · Investigational New Drugs · doi:10.1007/s10637-014-0142-1 · Cited by 26
Sun, X., Zhu, D., Cai, Y., Shi, G., Gao, M., & Zheng, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s193783 · Cited by 26
A novel mechanism of irinotecan targeting MDM2 and Bcl-xL
Lee, B., Min, J. A., Nashed, A., Lee, S.-O., Yoo, J. C., Chi, S., & Yi, G. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.009 · Cited by 25
Bernards, N., Ventura, M., Fricke, I. B., Hendriks, B. S., Fitzgerald, J. B., Lee, H., & Zheng, J. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00540 · Cited by 25
Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective
Mehmood, R. K. (2014) · World Journal of Oncology · doi:10.14740/wjon830w · Cited by 24
Naumann, J. A., Widen, J. C., Jonart, L. A., Ebadi, M., Tang, J. H., Gordon, D. J., Harki, D. A., & Gordon, P. M. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00774 · Cited by 24
Yang, X., Li, C., Xu, M., Zhao, H., & Wang, D. (2015) · BMC Cancer · doi:10.1186/s12885-015-1978-2 · Cited by 22
Hong, Y. S., Lee, H. R., Park, S. H., Lee, S. C., Hwang, I. G., Park, B.-B., Lee, J., Ahn, J. S., Ahn, M.-J., Lim, H. Y., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603500 · Cited by 21
FOLFIRI as second-line treatment of metastatic biliary tract cancer patients
Caparica, R., Lengelé, A., Nga, W. T. B., & Hendlisz, A. (2019) · Autopsy and Case Reports · doi:10.4322/acr.2019.087 · Cited by 21
Irinotecan in epithelial ovarian cancer.
Gershenson, D. M. (2002) · PubMed · Cited by 18
Vienot, A., Chevalier, H., Bolognini, C., Gherga, E., Klajer, É., Meurisse, A., Jary, M., Kim, S. C. H., d’Engremont, C., Nguyen, T., et al. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i3.332 · Cited by 18
Aparicio, T., Linot, B., Malicot, K. L., Bouché, O., Boige, V., François, É., Ghiringhelli, F., Legoux, J.-L., Abdelghani, M. B., Phelip, J., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.01.146 · Cited by 17
Ramalingam, S. S., Foster, J., Gooding, W. E., Evans, T. L., Sulecki, M., & Belani, C. P. (2010) · Cancer · doi:10.1002/cncr.24753 · Cited by 17
Irinotecan for the treatment of cervical cancer.
Verschraegen, C. F. (2002) · PubMed · Cited by 17
Pectasides, D. G., Mylonakis, N., Farmakis, D. T., Nikolaou, M., Koumpou, M., Katselis, I., Gaglia, A., Kostopoulou, V., Karabelis, A., & Kosmas, C. (2003) · PubMed · Cited by 17
Erdem, G. U., Bozkaya, Y., Özdemir, N., Demirci, N. S., Yazıcı, O., & Zengin, N. (2017) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2017.2258 · Cited by 16
Systemic Therapy for Small Cell Lung Cancer
Levy, B. P., Saxena, A., & Schneider, B. J. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0100 · Cited by 16
Uehara, K., Ishiguro, S., Hiramatsu, K., Nishio, H., Takeuchi, E., Takahari, D., Yoshioka, Y., Takahashi, Y., Ebata, T., Yoshimura, K., et al. (2011) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyr115 · Cited by 12
Tsuboya, A., Fujita, K., Kubota, Y., Ishida, H., Taki-Takemoto, I., Kamei, D., Iwai, S., & Sasaki, Y. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1347-7 · Cited by 12
The emerging world role of irinotecan in lung cancer.
Langer, C. J. (2001) · PubMed · Cited by 10
Genotoxic effects of irinotecan combined with the novel platinum(II) complexes in human cancer cells
Kontek, R., Matlawska‐Wasowska, K., Kalinowska‐Lis, U., & Marciniak, B. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.07.005 · Cited by 9
Self-citationProteomic analysis of cell lines to identify the irinotecan resistance proteins
Peng, X., Gong, F., Wei, M., Chen, X., Chen, Y., Cheng, K., Gao, F., Xu, F., Bi, F., & Liu, J. (2010) · Journal of Biosciences · doi:10.1007/s12038-010-0064-9 · Cited by 8
Reed, B. R., Yakovleva, L. M., Shuman, S., & Ghose, R. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00042 · Cited by 6
Irinotecan plus cisplatin in small-cell lung cancer.
Sandler, A. (2002) · PubMed · Cited by 5
Geredeli, Ç., & Yaşar, N. (2018) · World Journal of Surgical Oncology · doi:10.1186/s12957-018-1359-9 · Cited by 5
Cited by
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
“Supercoiled DNA emerging during the above-mentioned processes can unwind and efficiently function as a template upon the introduction of single- or double-strand breaks (SSBs or DSBs) by topoisomerase type I and II enzymes, respectively [67].”
BackgroundSelf-citationStatus and Challenges of Plant-Anticancer Compounds in Cancer Treatment
Garcia-Oliveira, P., Otero, P., Pereira, A. G., Chamorro, F., Carpena, M., Echave, J., Fraga-Corral, M., Simal-Gandara, J., & Prieto, M. A. (2021) · Pharmaceuticals · doi:10.3390/ph14020157 · Cited by 303
“These issues could be solved by new drug formulations containing nanoparticles, polymer conjugates, dendrimers, peptides, and carbohydrates [64].”
BackgroundPEGylated therapeutics in the clinic
Gao, Y., Joshi, M., Zhao, Z., & Mitragotri, S. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10600 · Cited by 233
“124,125 The need for PEGylation of traditionally considered small molecule drugs is pressing, given that many effective small molecule drugs, such as irinotecan, 126 suffer from undesirable pharmacokinetic profiles.”
BackgroundTreatment for liver cancer: From sorafenib to natural products
Man, S., Luo, C., Yan, M., Zhao, G., Ma, L., & Gao, W. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113690 · Cited by 177
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Metadata
- Authors
- Kciuk, M., Marciniak, B., & Kontek, R.
- Affiliations
- University of Łódź (PL)
- Corresponding author
- Kciuk, Mateusz
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-07-12
- Volume
- 21
- Issue
- 14
- Pages
- 4919
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7404108
- OpenAlex
- W3041813955
- Cited by
- 266
- References
- 136
- Citations by year
- 2026: 29 · 2025: 76 · 2024: 66 · 2023: 50 · 2022: 29 · 2021: 13 · 2020: 3
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, camptothecin, SN-38, pharmacogenetics, drug metabolism, drug toxicity, combination chemotherapy, liposomal formulation, dendrimers, nanoparticles, drug resistance, anticancer agents
- MeSH terms
- Irinotecan, Antineoplastic Combined Chemotherapy Protocols, DNA, Neoplasm, Dosage Forms, Drug Compounding, Drug Synergism, Female, Humans, Male, Models, Molecular, Neoplasm Proteins, Neoplasms, Nucleic Acid Conformation, Prodrugs, Protein Conformation, Molecular Structure, Drug Resistance, Neoplasm, Polymorphism, Single Nucleotide, Topoisomerase I Inhibitors, Activation, Metabolic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.